China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Net Asset Momentum
China Resources Double-Crane Pharmaceutical Co Ltd (600062) recorded a net asset momentum of -5.8% as of December 2024, with net assets of CN¥11.11 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See what is China Resources Double-Crane Pharmaceuti's book value for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
China Resources Double-Crane Pharmaceutical Co Ltd Net Asset Momentum (1994–2024)
This chart tracks China Resources Double-Crane Pharmaceutical Co Ltd's year-over-year net asset growth across 31 annual reporting periods from 1994 to 2024. The most recent momentum reading is -5.8%, with net assets of CN¥11.11 Billion CNY as of December 2024. For live market cap and overall valuation, see China Resources Double-Crane Pharmaceuti market cap and net worth.
Annual Net Asset History for China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)
The table below shows the complete annual net asset history for China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024, covering 31 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check 600062 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | CN¥11.11 Billion | CN¥16.69 Billion | CN¥5.57 Billion | ▼ -5.8% |
| 2023 | CN¥11.79 Billion | CN¥15.43 Billion | CN¥3.64 Billion | ▲ +9.9% |
| 2022 | CN¥10.73 Billion | CN¥14.48 Billion | CN¥3.75 Billion | ▲ +2.4% |
| 2021 | CN¥10.48 Billion | CN¥13.68 Billion | CN¥3.20 Billion | ▲ +11.7% |
| 2020 | CN¥9.38 Billion | CN¥12.42 Billion | CN¥3.04 Billion | ▲ +8.1% |
| 2019 | CN¥8.68 Billion | CN¥11.28 Billion | CN¥2.60 Billion | ▲ +9.7% |
| 2018 | CN¥7.91 Billion | CN¥10.31 Billion | CN¥2.40 Billion | ▲ +0.8% |
| 2017 | CN¥7.85 Billion | CN¥9.44 Billion | CN¥1.59 Billion | ▲ +11.5% |
| 2016 | CN¥7.04 Billion | CN¥8.24 Billion | CN¥1.20 Billion | ▲ +9.4% |
| 2015 | CN¥6.43 Billion | CN¥7.76 Billion | CN¥1.33 Billion | ▲ +13.2% |
| 2014 | CN¥5.68 Billion | CN¥6.62 Billion | CN¥934.93 Million | ▲ +6.5% |
| 2013 | CN¥5.34 Billion | CN¥6.48 Billion | CN¥1.14 Billion | ▲ +13.4% |
| 2012 | CN¥4.71 Billion | CN¥6.51 Billion | CN¥1.80 Billion | ▲ +8.4% |
| 2011 | CN¥4.34 Billion | CN¥6.08 Billion | CN¥1.73 Billion | ▲ +10.6% |
| 2010 | CN¥3.93 Billion | CN¥5.21 Billion | CN¥1.28 Billion | ▲ +11.1% |
| 2009 | CN¥3.53 Billion | CN¥4.72 Billion | CN¥1.18 Billion | ▲ +12.2% |
| 2008 | CN¥3.15 Billion | CN¥4.27 Billion | CN¥1.12 Billion | ▲ +33.2% |
| 2007 | CN¥2.36 Billion | CN¥3.67 Billion | CN¥1.31 Billion | ▲ +18.5% |
| 2006 | CN¥2.00 Billion | CN¥3.26 Billion | CN¥1.26 Billion | ▲ +2.9% |
| 2005 | CN¥1.94 Billion | CN¥3.81 Billion | CN¥1.87 Billion | ▲ +12.3% |
| 2004 | CN¥1.73 Billion | CN¥4.03 Billion | CN¥2.30 Billion | ▲ +0.6% |
| 2003 | CN¥1.72 Billion | CN¥4.26 Billion | CN¥2.54 Billion | ▲ +7.0% |
| 2002 | CN¥1.60 Billion | CN¥3.62 Billion | CN¥2.01 Billion | ▲ +7.7% |
| 2001 | CN¥1.49 Billion | CN¥2.75 Billion | CN¥1.26 Billion | ▲ +74.2% |
| 2000 | CN¥855.27 Million | CN¥1.48 Billion | CN¥628.89 Million | ▲ +20.3% |
| 1999 | CN¥711.23 Million | CN¥1.18 Billion | CN¥473.60 Million | ▲ +31.4% |
| 1998 | CN¥541.45 Million | CN¥741.02 Million | CN¥199.57 Million | ▲ +14.5% |
| 1997 | CN¥472.91 Million | CN¥574.69 Million | CN¥101.78 Million | ▲ +346.9% |
| 1996 | CN¥105.81 Million | CN¥154.30 Million | CN¥48.49 Million | ▲ +2.6% |
| 1995 | CN¥103.12 Million | CN¥132.29 Million | CN¥29.17 Million | ▲ +8.7% |
| 1994 | CN¥94.91 Million | CN¥131.33 Million | CN¥36.42 Million | — |